GPX4 and neoplasm: ML210 demonstrates significant antitumor efficacy in preclinical models by efficiently penetrating the blood–brain barrier (BBB), selectively inhibiting GPX4 and inducing ferroptosis in glioblastoma, resulting in a 50% reduction in tumor volume [62].